investors & media
bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.
With a dedicated focus on severe genetic diseases, bluebird has industry-leading clinical programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.
Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.
NASDAQ: (common stock)
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Current standard of care relies on regular red blood cell transfusions and iron management that carry the risk of progressive multi-organ damage and increased risk of morbidity and mortality If approved, beti-cel will be the first potentially curative gene therapy option for people withRead more
If approved, eli-cel will be the first and only gene therapy for the treatment of early active CALD, a rare neurodegenerative disease that primarily affects young children and leads to irreversible loss of neurologic function and death PDUFA goal date is set for September 16, 2022 SOMERVILLE, Mass.Read more
- BLAs for beti-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, to be discussed at an FDA Advisory Committee Meeting on June 9-10, 2022 - SOMERVILLE, Mass. --(BUSINESS WIRE)--Jun. 9, 2022-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announcedRead more